Navigation Links
Benda Pharmaceutical Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/31/2008

HUBEI PROVINCE, China, March 31 /Xinhua-PRNewswire-FirstCall/ -- Benda Pharmaceutical, Inc. (OTC Bulletin Board: BPMA), a China-based pharmaceutical company producing both Gendicine(R), a commercialized gene therapy medicine for the treatment of cancer, and traditional Chinese and conventional medicines, today announced financial results for the fourth quarter and fiscal year ended December 31, 2007. The Company plans to file its Annual Report with the SEC today.

Full Year Ended December 31, 2007

Revenue in the fiscal year 2007 increased 66% to $26.4 million from $15.9 million in 2006. Revenue performance reflects increased sales from Benda's subsidiaries, Benda Ebei and Jiangling Benda, and approximately $5.8 million in revenue from Gendicine since Benda's acquisition of SiBiono in April 2007.

Gross profit during this period increased 97% to $12.5 million from $6.3 million in 2006. Gross margin increased 770 basis points to 47.3% from 39.6% in the same period of 2006, reflecting the higher margin revenue contribution from Gendicine sales.

The Company's general and administrative expenses in 2007 were $13.9 million compared to $2.5 million in 2006. The $11.4 million increase in 2007 was driven by $9.4 million in non-recurring costs, including $8.4 million in non-cash stock compensation expense for consulting services related to the acquisition of SiBiono and a $1.0 million cash penalty recorded in 2007 because of the late submission of the effective registration statement. For additional information regarding these items, please refer to the Company's Annual Report. Excluding these non-recurring expenses, operating income for the year 2007 would have been $5.8 million, up 92% from $3.0 million in 2006.

In 2007, Benda recognized $2.9 million in interest expense, related to the Company's convertible note issued in March 2007.

Mr. Charles Wan, Chief Executive Officer of Benda Pharmaceutical, commented, "We realized signi
'/>"/>

SOURCE Benda Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Pharmaceutical Strategic Initiatives Adds Anne Sexton, MD, MS to Management Team
2. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
3. Caraco Pharmaceutical Laboratories Ltd. To Market Generic Ethyol(R)
4. China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results
5. Barr Pharmaceuticals, Inc. Executive Bios
6. Biotest Pharmaceuticals Corporation Responds to Orphan Drug Act Announcement
7. Tabula Rasa Strategies(TM), LLC, Announces Their Company Launch - A Clean Slate Approach to the Practice of Pharmaceutical Care
8. Honeywell Expands Aclar(R) Production for Pharmaceutical Industry
9. Surveys Find Key Changes in the Role of the Pharmaceutical CFO
10. KV Pharmaceutical Company Completes Financial Restatement with the Filing of Fiscal 2007 Form 10-K
11. AUDIO from Medialink and Solvay Pharmaceuticals: Men with Type 2 Diabetes at Increased Risk for Low Testosterone Should Talk to Their Doctors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/3/2008)...- Inc. Magazine recently included,Connolly Consult...ing,private companies in the country. The list is ...segment of the economy -- America,s,independent-mi...ies,represent the backbone of the U.S. economy., ...03/NY36880LOGO ), Connolly Consulting,s consiste...
(Date:10/3/2008)... Discrimination; Recognizes,Importance of Mental H.../PRNewswire-USNewswire/ -- Mental Health,America t...approval of a,mental health parity legislation tha...ion against Americans with mental health and subst...lans., The legislation, which recognizes the impo...
(Date:10/3/2008)...search Foundation(R) Collection of, Bouquets to T...Research, LOS ANGELES, Oct. 3 /PRNewswire/ -- Tel...g only hand-arranged, hand-delivered floral,arrang...nth-long,collaboration with The City of Hope, John... Cancer Center in southern California and national...
(Date:10/3/2008)...- As the population ages, a big,question employers...e the,financial crunch of an illness?", In most c...eck to,paycheck and now need two incomes to provid... spouses becomes critically ill and unable to work...ut the healthy,employee/spouse is strained by the ...
Breaking Medicine News(10 mins):Health News:Connolly Consulting Makes the 2008 Inc. Magazine's List of America's 5000 Fastest Growing Companies 2Health News:Mental Health America Hails Approval of Federal Parity Legislation 2Health News:Mental Health America Hails Approval of Federal Parity Legislation 3Health News:Teleflora and Nationally Recognized Hospitals to Honor Women Battling Breast Cancer 2Health News:Teleflora and Nationally Recognized Hospitals to Honor Women Battling Breast Cancer 3Health News:Can Your Employees Survive the Financial Crunch of an Illness? 2
...A large number of doctors in Portugal were refusin...tting abortions up to the 10th week of pregnancy ....ctors" and press reports indicated at least nine p...a total of 50 could not guarantee the procedure. ...
...China will mass-produce a Cuban pesticide effectiv...n ministry said Sunday . Cuban scientists develop...ls larvae of the Aedes aegypti mosquito, the dengu...statement said. According to the agreement, China...
...A new study has examined whether a vaccine that of...asing risky behaviour , as a false sense of securi...herwise would be. While the study looks at the r... its authors suggest the research also sheds light...
...A recent research has found that a suntan is the b...fects of ultraviolet (UV) light .Researchers at th...in Boston have conducted a series of experiments a...the body from the cancerous effects of ultraviolet...
Other Medicine News:Health News:Efficacy of Lyme Disease Vaccination Examined 2
(Date:10/3/2008)...e newest study site, PHILADELPHIA, Oct. 3 /PRNews...ladelphia today received a contract to manage a ne...ldren,s Hospital will manage local,participation, ...ty, New,Jersey. The study is funded by the Nationa... approximately 1,000 families in Burlington,County...
(Date:10/2/2008)...f Rosetta Genomics, microRNA-based,Test, miRview(T...n Squamous non Small Cell Lung Cancer, With C...view(TM) Technology First Approved for Clinical us... Molecular Pathology Lab ... to Launch miRview(TM) Squamous Later This Ye...
(Date:10/2/2008)...stCall/ - AEterna Zentaris Inc.,(NASDAQ: AEZS ; T...ed on,endocrine therapy and oncology, today report... recruitment for its Phase 2 trial in ovarian canc...hormone (LHRH) agonist,linked to doxorubicin. The ...uitment was taken following recent first stage dat...
(Date:10/1/2008)...ingual lozenge) developed to be the first sleep a... when patients awaken and have difficulty .../- Transcept Pharmaceuticals,Inc., a...announced today,that it has submitted a New Drug A...tration (FDA) for its lead product candidate, Inte...
Breaking Medicine Technology:The Children's Hospital of Philadelphia Announces New Regional Participant in The National Children's Study 2Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 2Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 3Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 4Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 5AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 3AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 5Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 2Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 3Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 4Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 5Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 6Dawning Technologies Inc and Medical Automation Systems Inc to Develop a Business Partnership 20850 1Dawning Technologies Inc and Medical Automation Systems Inc to Develop a Business Partnership 20850 2Haemacure Reports on Financing Progress and Second Quarter Results 20846 1Haemacure Reports on Financing Progress and Second Quarter Results 20846 2Haemacure Reports on Financing Progress and Second Quarter Results 20846 3US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings 2288 1US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings 2288 2US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings 2288 3US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings 2288 4US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings 2288 5Vaccine may double survival in patients with deadly brain tumors 20841 1Vaccine may double survival in patients with deadly brain tumors 20841 2
Straight shafts with 1 x 2 teeth and serrated handle with polished finish.
Smooth 90 degree jaws with locking screw maintain proper stretch of sleeve for securing silicone bands.
Ergotec Vetriretinal Instrument System. Extra fine angled tips (3 mm). 20 gauge shaft tapering to 23 gauge, 10 mm from tip. Overall length from rear rotation knob to tip.
Ergotec Vetriretinal Instrument System. Ultra-fine 0.8 mm tips. Angled 40 degrees. 20 gauge shaft tapers to 23 gauge.
Medicine Products: